{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:43:30Z","timestamp":1790657010607,"version":"4.1.0"},"reference-count":38,"publisher":"American Diabetes Association","issue":"3","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,3,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Oxidative stress has been shown to be increased in the postprandial period in patients with diabetes and has been implicated in the pathogenesis of micro- and macrovascular complications. The aim of this post hoc analysis was to assess the effects of pramlintide, an amylin analog shown to reduce postprandial glucose excursions in patients with diabetes, on markers of oxidative stress in the postprandial period.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin. The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.<\/jats:p>\n               <jats:p>RESULTS\u2014Compared with placebo, pramlintide treatment significantly reduced postprandial excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP (P &amp;lt; 0.03 for all comparisons). Correlation analyses adjusted for treatment revealed a significant association between postprandial mean incremental area under the curve from 0 to 4 h (AUC0\u20134 h) for glucose and postprandial mean incremental AUC0\u20134 h for each measure of oxidative stress (r = 0.75, 0.54, and \u22120.63 for nitrotyrosine, ox-LDL, and TRAP, respectively; P &amp;lt; 0.001 for all correlations).<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014These findings indicate that the postprandial glucose-lowering effect of pramlintide in type 1 diabetes is associated with a significant reduction in postprandial oxidative stress.<\/jats:p>","DOI":"10.2337\/diacare.28.3.632","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"632-637","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":60,"title":["Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes"],"prefix":"10.2337","volume":"28","author":[{"given":"Antonio","family":"Ceriello","sequence":"first","affiliation":[{"name":"Department of Pathology and Medicine, Experimental and Clinical, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Piconi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medicine, Experimental and Clinical, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Quagliaro","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medicine, Experimental and Clinical, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Ruggles","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice A.","family":"Gloster","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maggs","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weyer","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031218460020400_R1","doi-asserted-by":"crossref","unstructured":"Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care\u200819: 257\u2013267, 1996","DOI":"10.2337\/diacare.19.3.257"},{"key":"2022031218460020400_R2","doi-asserted-by":"crossref","unstructured":"Rosen P, Naworth PP, King G, Moller W, Tritschler HJ, Packer L: The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev\u200817:189\u2013212, 2001","DOI":"10.1002\/dmrr.196"},{"key":"2022031218460020400_R3","doi-asserted-by":"crossref","unstructured":"West IC: Radicals and oxidative stress in diabetes. Diabet Med\u200817:171\u2013180, 2000","DOI":"10.1046\/j.1464-5491.2000.00259.x"},{"key":"2022031218460020400_R4","doi-asserted-by":"crossref","unstructured":"Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature\u2008414:813\u2013820, 2001","DOI":"10.1038\/414813a"},{"key":"2022031218460020400_R5","doi-asserted-by":"crossref","unstructured":"Ceriello A: Acute hyperglycaemia and oxidative stress generation. Diabet Med\u200814 (Suppl. 3):S45\u2013S49, 1997","DOI":"10.1002\/(SICI)1096-9136(199708)14:3+<S45::AID-DIA444>3.0.CO;2-R"},{"key":"2022031218460020400_R6","doi-asserted-by":"crossref","unstructured":"Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C: Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care\u200821:1529\u20131533, 1998","DOI":"10.2337\/diacare.21.9.1529"},{"key":"2022031218460020400_R7","doi-asserted-by":"crossref","unstructured":"Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism\u200848:1503\u20131508, 1999","DOI":"10.1016\/S0026-0495(99)90237-8"},{"key":"2022031218460020400_R8","doi-asserted-by":"crossref","unstructured":"Ceriello A: The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia\u200846 (Suppl. 1):M9\u2013M16, 2003","DOI":"10.1007\/s00125-002-0931-5"},{"key":"2022031218460020400_R9","doi-asserted-by":"crossref","unstructured":"Edelman SV, Weyer C: Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second \u03b2-cell hormone. Diabetes Technol Ther\u20084:175\u2013189, 2002","DOI":"10.1089\/15209150260007390"},{"key":"2022031218460020400_R10","doi-asserted-by":"crossref","unstructured":"Buse JB, Weyer C, Maggs DG: Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes\u200820:137\u2013144, 2002","DOI":"10.2337\/diaclin.20.3.137"},{"key":"2022031218460020400_R11","doi-asserted-by":"crossref","unstructured":"Fineman M, Koda J, Weyer C, Shen LZ, Strobel SA, Maggs D, Kolterman O: The human amylin analogue pramlintide corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism\u200851:636\u2013641, 2002","DOI":"10.1053\/meta.2002.32022"},{"key":"2022031218460020400_R12","doi-asserted-by":"crossref","unstructured":"Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia\u200841:577\u2013583, 1998","DOI":"10.1007\/s001250050949"},{"key":"2022031218460020400_R13","doi-asserted-by":"crossref","unstructured":"Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD: Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil\u200814:123\u2013131, 2002","DOI":"10.1046\/j.1365-2982.2002.00311.x"},{"key":"2022031218460020400_R14","doi-asserted-by":"crossref","unstructured":"Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A: Effect of 14 days\u2019 subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia\u200839:492\u2013499, 1996","DOI":"10.1007\/BF00400683"},{"key":"2022031218460020400_R15","doi-asserted-by":"crossref","unstructured":"Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes\u200846:632\u2013636, 1997","DOI":"10.2337\/diabetes.46.4.632"},{"key":"2022031218460020400_R16","doi-asserted-by":"crossref","unstructured":"Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O: The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism\u200848:935\u2013941, 1999","DOI":"10.1016\/S0026-0495(99)90232-9"},{"key":"2022031218460020400_R17","doi-asserted-by":"crossref","unstructured":"Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care\u200825:724\u2013730, 2002","DOI":"10.2337\/diacare.25.4.724"},{"key":"2022031218460020400_R18","doi-asserted-by":"crossref","unstructured":"Hollander PA, Levy P, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: a 1 year randomized controlled trial. Diabetes Care\u200826:784\u2013790, 2003","DOI":"10.2337\/diacare.26.3.784"},{"key":"2022031218460020400_R19","doi-asserted-by":"crossref","unstructured":"Weyer C, Gottlieb A, Kim D, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in patients with type 1 diabetes: a dose-timing study. Diabetes Care\u200826:3074\u20133079, 2003","DOI":"10.2337\/diacare.26.11.3074"},{"key":"2022031218460020400_R20","doi-asserted-by":"crossref","unstructured":"Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C: Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev\u200820:55\u201360, 2004","DOI":"10.1002\/dmrr.419"},{"key":"2022031218460020400_R21","doi-asserted-by":"crossref","unstructured":"Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the plasma: evidence of oxidative stress. Diabetologia\u200844:834\u2013838, 2001","DOI":"10.1007\/s001250100529"},{"key":"2022031218460020400_R22","doi-asserted-by":"crossref","unstructured":"Ghiselli A, Serafini M, Maiani G, Azzini E, Ferro-Luzzi A: A fluorescence-based method for measuring total plasma antioxidant capability. Free Rad Biol Med\u20088:29\u201336, 1995","DOI":"10.1016\/0891-5849(94)00102-P"},{"key":"2022031218460020400_R23","doi-asserted-by":"crossref","unstructured":"Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA\u2008289:1675\u20131680, 2003","DOI":"10.1001\/jama.289.13.1675"},{"key":"2022031218460020400_R24","doi-asserted-by":"crossref","unstructured":"Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O\u2019Leary DH, Genuth S, Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med\u2008348:2294\u20132303, 2003","DOI":"10.1056\/NEJMoa022314"},{"key":"2022031218460020400_R25","doi-asserted-by":"crossref","unstructured":"Weis U, Turner B, Gibney J, Watts GF, Burke V, Shaw KM, Cummings MH: Long-term predictors of coronary artery disease and mortality in type 1 diabetes. QJM\u200894:623\u2013630, 2001","DOI":"10.1093\/qjmed\/94.11.623"},{"key":"2022031218460020400_R26","doi-asserted-by":"crossref","unstructured":"Tsai EC, Hirsch IB, Brunzell JD Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes\u200843:1010\u20131014, 1994","DOI":"10.2337\/diabetes.43.8.1010"},{"key":"2022031218460020400_R27","doi-asserted-by":"crossref","unstructured":"Santini SA, Giampero M, Giardina B, Cotroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G: Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes\u200846:1853\u20131858, 1997","DOI":"10.2337\/diabetes.46.11.1853"},{"key":"2022031218460020400_R28","doi-asserted-by":"crossref","unstructured":"Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda G, Santini SA: Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care\u200825:370\u2013375, 2002","DOI":"10.2337\/diacare.25.2.370"},{"key":"2022031218460020400_R29","doi-asserted-by":"crossref","unstructured":"Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G: Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab\u200888:1624\u20131628, 2003","DOI":"10.1210\/jc.2002-021525"},{"key":"2022031218460020400_R30","doi-asserted-by":"crossref","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet\u2008359:2072\u20132077, 2002","DOI":"10.1016\/S0140-6736(02)08905-5"},{"key":"2022031218460020400_R31","doi-asserted-by":"crossref","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA\u2008290:486\u2013494, 2003","DOI":"10.1001\/jama.290.4.486"},{"key":"2022031218460020400_R32","doi-asserted-by":"crossref","unstructured":"Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke\u200835:1073\u20131078, 2004","DOI":"10.1161\/01.STR.0000125864.01546.f2"},{"key":"2022031218460020400_R33","doi-asserted-by":"crossref","unstructured":"Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J\u200825:10\u201316, 2004","DOI":"10.1016\/S0195-668X(03)00468-8"},{"key":"2022031218460020400_R34","doi-asserted-by":"crossref","unstructured":"Esposito K, Giugliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation\u2008110:214\u2013219, 2004","DOI":"10.1161\/01.CIR.0000134501.57864.66"},{"key":"2022031218460020400_R35","unstructured":"Verges BL: Dyslipidaemia in diabetes mellitus: review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab\u200825 (Suppl. 3):32\u201340, 1999"},{"key":"2022031218460020400_R36","doi-asserted-by":"crossref","unstructured":"Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care\u200826:1\u20138, 2003","DOI":"10.2337\/diacare.26.1.1"},{"key":"2022031218460020400_R37","doi-asserted-by":"crossref","unstructured":"Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation\u2008106:1211\u20131218, 2002","DOI":"10.1161\/01.CIR.0000027569.76671.A8"},{"key":"2022031218460020400_R38","doi-asserted-by":"crossref","unstructured":"Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D: Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes\u200853:701\u2013710, 2004","DOI":"10.2337\/diabetes.53.3.701"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/28\/3\/632\/654705\/zdc00305000632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/28\/3\/632\/654705\/zdc00305000632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:51:37Z","timestamp":1647114697000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/28\/3\/632\/27787\/Effects-of-Pramlintide-on-Postprandial-Glucose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.28.3.632","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,1]]}}}